Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teleflex Says It Will Lose $9m – And Maybe More – Due To EtO Plant Shutdown

Executive Summary

The medical device-maker says it will lose millions by the end of the fiscal year because Georgia regulators have temporarily shut down Sterigenics’ ethylene oxide sterilization (EtO) facility near Atlanta. With no news on when it will reopen, the company says it may lose even more money next year.

You may also be interested in...



Teleflex Subsidiary Faces Federal False Claims Investigation

Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations. 

FDA Launches Pilot Program To Streamline EtO Facility, Process Changes

As concerns continue to mount over a potential shortage of medical devices due to the closure of ethylene oxide (EtO) facilities, the US agency is looking for nine sterilizers in a pilot project that could allow them to get facility and process changes approved faster.

Risk Of Sterilization Plant Shutdowns Across US Sends Shockwave Through Industry

While a number of US states are taking actions that could potentially ban or limit ethylene oxide (EtO) sterilization plants in their communities, the FDA, industry and others are raising the alarm that such moves could lead to a shortage of medical devices critical to patients.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT125869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel